ABBV-400 targets MET on the cell surface, is internalized, and releases a topoisomerase I inhibitor that blocks DNA replication and induces DNA damage/apoptosis in MET-positive cells; topoisomerase I is the intracellular payload target, not the binding antigen, so its expression alone does not make cells directly killed by the drug.